CCRF Inc., Beijing, China
11
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
Role: collaborator
To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.
Role: lead
Safety and Efficacy of Spinous Balloon Dilatation Catheter in CAD Treatment
Role: lead
Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions
Role: collaborator
A Prospective Evaluation of Clinical Impact of Physiology Versus Optical Coherence Tomography Guided PCI in STEMI Patients Without Undergoing Primary PCI
Role: lead
Multi Center Registry of Transcatheter Aortic Valve Replacement in Northeast China
Role: lead
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Role: collaborator
The Sensitivity and Specificity of CardioSimFFRct Analysis Software on Coronary Artery Stenosis
Role: lead
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV Fistula
Role: collaborator
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
Role: collaborator
The Safety and Efficacy of DIOR Balloon in Coronary Bifurcation Lesions
Role: lead
All 11 trials loaded